Luminari S, et al. - Given that marginal zone Lymphomas (MZL) represent indolent B cell non Hodgkin Lymphoma (INFL) and exhibit a heterogeneous clinical nature, and a recent work has reported stratification of overall survival (OS) in follicular NHL and in INFL by time to progression shorter than 24 months (POD24), researchers analyzed an extensive, international cohort of MZL as part of the NF10 prospective international registry headed by Fondazione Italiana Linfomi, to assess POD24 as a predictor of subsequent overall survival (OS) in this cohort. The NF10 study enrolled 1,325 patients. Among those, immediate treatment was planned right after lymphoma diagnosis in 321 pts with MZL. Overall 59 patients (18%) had POD24 confirmed. Patients with POD24 had a three-year OS of 53% with a HR of 19.5 (95%CI 8.4-45) than patients without POD24 (3 yr OS 95%). For the subgroup of splenic and extranodal MZL, the link between POD24 and OS was confirmed. In MZL, POD24 evaluation stratifies subsequent results and detects high risk group.